Cardiology Update 2nd Quarter

摘要

This update includes some landmark trials which were published in the last 3 months. Myocardial perfusion cardiovascular magnetic resonance imaging has shown some initial promise in trials, rivaroxaban reduced thromboembolic events in heart failure with coronary artery disease, drug-coated balloons show superiority to bare metal stents in patients with high bleeding risk, and various studies are also published to improve cardiac resynchronization therapy pacemaker response. In patients with stable angina, two strategies are often used to guide revascularization: one involves myocardial perfusion cardiovascular magnetic resonance imaging (MRI) and the other involves invasive angiography and measurement of fractional flow reserve (FFR). Whether a cardiovascular MRI-based strategy is noninferior to an FFR-based strategy with respect to major adverse cardiac events has not been established.